H. Mikamo, K. Kawazoe, K. Izumi
Oct 1, 1999
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Drugs
Abstract
New fluoroquinolones have been widely used for the treatment of various infections, because of their broad antibacterial spectrum, bactericidal activity and good pharmacokinetic profile.[1] Sitafloxacin is a new fluoroquinolone which was first synthesised by Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan.[2] Its in vitro activity is relatively potent compared with that of related quinolones.[3,4] Polymicrobial infections caused by aerobes and anaerobes are commonly seen in the female genital tract.[5] We therefore evaluated the efficacy of a new quinolone, sitafloxacin, using the model of rat uterine endometritis caused by representative pathogens. This is the first report of the in vivo activity of sitafloxacin.